China+1 strategy: India's mixed gains

  • Industry News
  • Dec 05,24
India’s strategic response to these challenges could determine the extent of its long-term gains from the evolving global supply chain realignments.
China+1 strategy: India's mixed gains

India's potential to benefit from the ‘China plus 1’ strategy remains promising despite initial setbacks in capitalising on early opportunities, according to Niti Aayog officials. They believe that as companies diversify supply chains from China, many have turned to Vietnam and Mexico.

However, these nations lack the capacity to fully meet global demands, positioning India—with its vast market and a decade of economic reforms—as a strong contender for future investments.

Niti Aayog member Arvind Virmani highlighted that former U.S. President Donald Trump's proposed 60% tariff on Chinese imports could create opportunities for Indian businesses, despite potential short-term disruptions.

The report also cautioned about the risks posed by the European Union’s carbon tax on high-emission exporters. India’s iron and steel industry, which constitutes 23.5% of the nation’s exports to the EU, is particularly vulnerable to this environmental levy.

India’s strategic response to these challenges could determine the extent of its long-term gains from the evolving global supply chain realignments.

(New Indian Express)

Related Stories

Policy Regulation
India and Chile Sign Terms of Reference for CEPA negotiations

India and Chile Sign Terms of Reference for CEPA negotiations

The CEPA aims to build upon the existing PTA between the two nations and seeks to encompass a broader range of sectors, including digital services, investment promotion and cooperation, MSME, critic..

Read more
Process Equipment
U.S. FDA to begin surprise checks abroad

U.S. FDA to begin surprise checks abroad

The FDA conducts approximately 12,000 domestic and 3,000 foreign inspections annually across over 90 countries.

Read more
Process Equipment
Trump’s pharma orders may hit Indian exports

Trump’s pharma orders may hit Indian exports

Trump's policy push aims to boost domestic production, grant faster approvals to U.S.-based facilities, conduct stricter inspections of foreign plants, and impose higher compliance fees on overseas ..

Read more

Related Products

Hi There!

Now get regular updates from IPF Magazine on WhatsApp!

Click on link below, message us with a simple hi, and SAVE our number

You will have subscribed to our Industrial News on Whatsapp! Enjoy

+91 84228 74016